BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Could a Fish Oil Backlash Wash Out Amarin Pharmaceuticals, Inc. (AMRN)?


11/19/2012 8:32:52 AM

Amarin Pharmaceuticals has been a biotech success story. Over the past two years the share price has tripled as the tiny company has managed to get approval from the Food and Drug Administration for Vascepa, a fish-oil pill that in many ways seems set to take market share from a blockbuster competitor, GlaxoSmithKline’s Lovaza. There are even reports that AstraZeneca and Teva Pharmaceuticals have considered buying it. But there may be rough seas ahead. Just a few years ago, Vascepa seemed like a marketer’s dream. Both it and Lovaza are approved to lower very high triglycerides, particles of fat in the blood that are thought to play a role in heart disease and pancreatitis. They do this because they contain long-chain omega-3 fatty acids, special “good” fats that are scarce in the human diet. Lovaza, which generated $240 million in sales for Glaxo last quarter, also raises low-density lipoprotein, the “bad cholesterol.” Vascepa doesn’t. There are other reasons that Vascepa might be better, but that alone is a pretty great marketing message. But now scientific publications, comments from doctors, and prescription trends all hint that the market for prescription fish oil in the U.S. may be shifting dramatically against fish oil and Lovaza use is going down. Investors have been focused on whether Vascepa has strong enough patent protection. But what if the real problem is the state of the fish oil market?

Read at Forbes

Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES